MTOR and cystic kidney disease: In the multivariate regression, the 11–17 years age group (1.67) and presence of anxiety (1.57), angiomyolipoma (1.51), and renal cysts (1.33) were significantly associated with the higher use of topical mTOR inhibitors (Table 2).